Guillain-Barré syndrome (GBS) is an autoimmune disease caused by a viral or viral infection and can be reduced. The most common HIV virus is Campylobacter June, which is a major cause of bacterial gastroenteritis worldwide. Immune-mediated immune responses may play a role in the development of GBS by interacting with brain tissue. Because the infected organism contains homologous epitopes, it initiates molecular and cell immune responses that interact with the ganglioside surface areas of the peripheral nerve (cell imitation). The immune response to epitopes in the upper layer of Schwann cells acts as a target for acute inflammatory demyelinating neuropathy (85%) caused by a reaction to epitopes found in the Schwann-cell surface or myelin. A strong axonal variation of GBS is caused by a reaction to epitopes found in the axonal membrane (15 percent of cases). Although caring for these people may be difficult, complete predictions are good. The basis of treatment is to provide the best supportive care and expectation and avoidance of complications. Patients in need of intubation and respiratory assistance should be admitted to the intensive care unit by 33% of cases. Immunomodilution with IgG infusions or plasma exchange therapy can accelerate the progression of this condition. Conclusion: High-quality intensive care is the necessary aspect of management of cases of GBS. Clinical studies show plasma exchange is one of the most promising treatments. Intravenous immunoglobulin is also effective but has side effects. Corticosteroid with IMG is insufficient and the evidence of this working is less.